Neurocrine Biosciences (NBIX) Capital Expenditures (2010 - 2026)

Neurocrine Biosciences (NBIX) has reported Capital Expenditures for 17 consecutive years, with $7.8 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Capital Expenditures fell 37.6% year-over-year to $7.8 million; the trailing twelve-month figure through Jun 2026 stood at $27.7 million (down 28.24% YoY), and the FY2025 full-year result was $34.0 million, down 10.99% from the prior year.
• Capital Expenditures slipped to $7.8 million in Q2 2026 per NBIX's latest filing, from $9.1 million in the prior quarter.
• Across five years, Capital Expenditures topped out at $13.2 million in Q3 2025 and bottomed at -$2.4 million in Q4 2025.
• Historically, Capital Expenditures has averaged $7.4 million across 5 years, with a median of $8.0 million in 2024.
• The sharpest annual moves came in 2023 and 2025: Capital Expenditures surged 547.06% in 2023, then plunged 132.88% in 2025.
• Over 5 years, Capital Expenditures stood at $1.8 million in 2022, then jumped by 200.0% to $5.4 million in 2023, then surged by 35.19% to $7.3 million in 2024, then slumped by 132.88% to -$2.4 million in 2025, then jumped by 425.0% to $7.8 million in 2026.
• According to Business Quant data, Capital Expenditures over the past three periods registered $7.8 million, $9.1 million, and -$2.4 million for Q2 2026, Q1 2026, and Q4 2025 respectively.